CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD.

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CNE000000Q94

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
21.2 ^CNY	-0.84%		+0.66%	+13.98%

Apr. 26	CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2%	MT
Apr. 26	CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication	MT

China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire China Resources Zizhu Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group Co., Ltd. for CNY3.1 billion.

February 25, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire China Resources Zizhu Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group Co., Ltd. for CNY3.1 billion on February 24, 2024. China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) signed the share transfer agreement to acquire China Resources Zizhu Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group Co., Ltd. for CNY3.1 billion on March 22, 2024. As of March 20, 2024, the transaction is approved by shareholders of China Resources Double-Crane Pharmaceutical Co.,Ltd.

Latest news about China Resources Double-Crane Pharmaceutical Co.,Ltd.

CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2%	Apr. 26	MT
CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication	Apr. 26	MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
CR Double-Crane Pharmaceutical Gets Nod to Trial Semaglutide Injection	Apr. 16	MT
CR Double-Crane Pharma Unit Receives Approval for Epilepsy Drug	Mar. 26	MT
CR Double-Crane Pharma's 2023 Profit Jumps 13%, Operating Income Climbs 6%	Mar. 22	MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. Proposes Cash Dividend	Mar. 21	CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
CR Double-crane Pharmaceutical Gets Nod to Market Doxazosin Mesylate Tablets	Mar. 12	MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire China Resources Zizhu Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group Co., Ltd. for CNY3.1 billion.	Feb. 25	CI
CR Double-Crane Pharma Gets Nod for Apixaban Tablets; Unit's Clozapine Orally Disintegrating Tablets Gets Greenlight for Proposed Amendments	Feb. 20	MT
CR Double-Crane Pharma's Unit Gets Nod to Market Lithium Carbonate Drug Ingredient	Feb. 08	MT
CR Double-Crane Pharmaceutical's Unit Gets Nod to Raise Strength of Viagra Drug	Jan. 31	MT
China Includes CR Double-Crane Pharmaceutical's Two Drugs in List of Insurance-Backed Drugs	Dec. 14	MT
CR Double-Crane Pharma Unit Gets Nod to Amend Sodium Lactate Ringer Injection's Details	Dec. 12	MT
China Resources Double-Crane Pharmaceutical Co.,Ltd.(SHSE:600062) dropped from Shanghai Stock Exchange 180 Value Index	Dec. 08	CI
China Resources Double-Crane Pharmaceutical Co.,Ltd.(SHSE:600062) dropped from SSE 180 Index	Dec. 08	CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. completed the acqyusution 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd.	Nov. 02	CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
CR Double-Crane Pharma to Buy 90% Stake in Local Peer For 260 Million Yuan	23-09-28	MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire an 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd for CNY 260 million	23-09-27	CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
CR Double-Crane Pharma Gets Regulatory Nod to Amend Instructions for Lansoprazole for Injection	23-08-09	MT
CR Double-Crane Pharma Units Get Regulatory Approvals in China	23-07-11	MT
CR Double-Crane Pharma Unit Secures Registration Approval for Gout Drug in China	23-06-21	MT

Chart China Resources Double-Crane Pharmaceutical Co.,Ltd.

Duration

Period

Chart China Resources Double-Crane Pharmaceutical Co.,Ltd.

More charts

Company Profile

CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The Company's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The Company distributes its products mainly in domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for China Resources Double-Crane Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.2 CNY

Average target price

24.91 CNY

Spread / Average Target

+17.52%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD.	+13.98%	2.99B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals